Nielk
Senior Member
- Messages
- 6,970
Where is the money coming from to fund this
Thanks for the info.The IOM website states that panelists are not paid.
Is this question for me, Eco? I think our posts crossed, but as I said above, I do not know how much the IOM contract will cost. I've heard that IOM studies usually cost around $1 million, but I'm sure that varies a lot.
Regarding whether the CAA or Dr. Vernon have a conflict of interest re: IOM, I have to point out that no one has offered any documentation showing that they do. When I was on the Board (until the end of 2011) the Association had a very robust conflict of interest policy, and the Board was vigilant for conflicts. I assume that is still the case, particularly in the absence of documentation to the contrary. Also, IOM does not pay its panelists.
Regarding the statement that the Association has a general financial interest in a broader definition because it will allow them to raise more money, that doesn't make much sense. If that were true, then EVERY organization that serves our patient population would have the same conflict of interest. So does PANDORA or WPI or Mass CFIDS or PR have a conflict of interest because a broader definition would help them raise more money? I don't think so.
Where is the money coming from to fund this
Regarding the statement that the Association has a general financial interest in a broader definition because it will allow them to raise more money, that doesn't make much sense. If that were true, then EVERY organization that serves our patient population would have the same conflict of interest. So does PANDORA or WPI or Mass CFIDS or PR have a conflict of interest because a broader definition would help them raise more money? I don't think so.
Although you do have to ask yourself, why at this time is there now any interest to define criteria after 25 years by HSS. Especially while Lipkin and others are still in the process of looking for biomarkers.
Regarding the statement that the Association has a general financial interest in a broader definition because it will allow them to raise more money, that doesn't make much sense. If that were true, then EVERY organization that serves our patient population would have the same conflict of interest. So does PANDORA or WPI or Mass CFIDS or PR have a conflict of interest because a broader definition would help them raise more money? I don't think so.
If they're doing the same things they did to Gulf War Illness, it'll be more like NICE guidelines. I think the GWI document was 118 pages long, and had a lot of stuff about treating comorbid problems. I didn't read the rest, but presumably it also talks about treating the primary GWI (and every other conceivable related topic).I still do not fully understand if IOM are attempting to write the equivalent to the Full NICE Clinical Guideline, (which tells the NHS how to implement and to diagnose as well as 'treat'), or are more 'simply' trying to arrive at a single definition/criteria and - we hear now - nomen for 'the disease' or diseases.
To be blunt: because we asked for it?
I mean the way in which this contract was passed to IOM on the QT, was reprehensible, and communication with interested parties including CFSAC was virtually non-existent; but - and correct me if I am wrong please - HHS can claim that CFSAC and the community at large have been expressing their displeasure for many many many years.
I don't condone the way they have gone about this - but something has been on the cards (and in my view) overdue for years over in the USA. Given all the 'debate' caused by this lack of communication, and the CFIDS letter, expert letter etc. I am left wondering if you'd consider yourselves lucky now to have even the NICE Guideline in place in the USA.
I mean when you consider the possible alternatives it's scary, e.g. the equivalent to the GWI outcome (though I have not read it myself other than all of the concerns expressed about it)*. Then again, if the CCC pass muster (and/or a combination of that and the ICC, with a dose of the methodology from NICE); you could end up with something better than we have - which I really do hope will be achieved, because then NICE might sit up and pay attention: and we could all see an improvement.
Here in a small country far, far, away; NICE are considering placing the CFS/ME Guideline on the 'static' list, pending any significant developments. Well, this could be one event of significance. If, when you have the full facts, you can all come together - not in full agreement - but in presenting a united front in terms of what it is you will accept, and why.
I still do not fully understand if IOM are attempting to write the equivalent to the Full NICE Clinical Guideline, (which tells the NHS how to implement and to diagnose as well as 'treat'), or are more 'simply' trying to arrive at a single definition/criteria and - we hear now - nomen for 'the disease' or diseases.
I must read Jennie's SOW document more carefully. But I don't think it necessary at the moment - until more research is able to point to a testable biomarker - that we need to have separate research and clinical definitions. I just cannot see the point with that - and neither can the 35.
(*Maybe the HHS have a directive to attempt to rationalise/collate/standardise etc. these Medically Unexplained Illnesses and we are next on the list?)
Where is the money coming from to fund this
To be fair, this is the most recent (October 2012) CFSAC recommendation:CFSAC's recommendation was not to reinvent the wheel and start to redefine the illness from scratch. What they asked and have been asking for years is for HHS to adopt the CCC which is in current use by clinicians and researchers. It is much improved over the CDC Fuduka which HHS has been glued to for 20 years. CFSAC then asked to have only ME/CFS experts work on improving on the CCC.
CFSAC recommends that you will promptly convene (by 12/31/12 or as soon as possible thereafter) at least one stakeholders’ (Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS)experts, patients, advocates) workshop in consultation with CFSAC members to reach a consensus for a case definition useful for research, diagnosis and treatment of ME/CFS beginning with the 2003 Canadian Consensus Definition for discussion purposes.
To be fair, this is the most recent (October 2012) CFSAC recommendation:
Your post reads, “adopt the CCC” and then “work on improving on the CCC.” The CFSAC recommendation reads, “reach a consensus for a case definition useful for research, diagnosis and treatment of ME/CFS beginning with the 2003 Canadian Consensus Definition for discussion purposes.”How does my post differ from CFSAC 10/12 recommendation?
The Committee should review the efforts that have already been done, including the 2003 ME/CFS Canadian Consensus Definition, the 2007 NICE Clinical Guidelines for CFS/ME, the 2010 Revised Canadian ME/CFS Definition, the 2011 ME International Consensus Criteria, and data from the ongoing CDC Multi-site Clinical Study of CFS.
I don't think that the argument that CAA has this conflict of interest should be dismissed as you are doing. I don't know if this potential conflict of interest actually does negatively color decisions made by CAA, BUT SOMETHING DOES. We see that historically, at least, CAA has consistently made decisions and actions inimical to the interests of patients. What EXACT conflicts of interest have made CAA act this way is unknowable for certain for those of us on the outside of CAA, but it is certain that some conflicts of interest have caused CAA to act against the interests of patients. Whether the specific one mentioned here has in fact been significant is uncertain, but should not be dismissed out of hand.
These other organizations you cite have NOT shown the type of anti-patient behavior that CAA has demonstrated, so their example is inapposite.